What’s behind PEPFAR’s funding cut threats?

June 12, 2019 |
Under fire for Truvada U.S. pricing at House hearing, Gilead chief O’Day touts R&D costs, asserts governments patents are void
Over 60 organizations condemn Trump administration’s treatment of migrants at border detention camps
Related Posts
Access to Medicines

Pharma’s alleged “brea...
PEPFAR Watch

PEPFAR is Rolling the Cloc...
Access to Medicines

Pharma Pricing Secrecy Run...